Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.36) per share which met the analyst consensus estimate. This is a 44 percent decrease over losses of $(0.25) per share from the same period last year.
HC Wainwright & Co. Maintains Buy on Mitek Systems, Lowers Price Target to $19
HC Wainwright & Co. analyst Scott Buck maintains Mitek Systems (NASDAQ:MITK) with a Buy and lowers the price target from $22 to $19.